Merck Sharp & Dohme LLC: Phase 3 study in Hyperlipidemia, Hypercholesterolemia (150 participants)
Merck Sharp & Dohme LLC: Phase 3 study in Hyperlipidemia, Hypercholesterolemia (150 participants). Its enrollment of 150 is above the median of 80 (71st percentile). Dated 49 days ago, it serves as a historical benchmark. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 150 · 71th percentile of 8,879 ClinicalTrialStartPulse records · 1.9x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) |
| NCT ID | NCT07821944 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Hyperlipidemia; Hypercholesterolemia |
| Intervention types | drug, other |
| Target enrollment | 150 |
| Site countries | India |
| Posted | 2026-09-16 |
| Planned start | 2026-10-15 |
| Event | Newly registered study |
| Event date | 2026-09-16 |
| enrollment percentile | 71th of 8,879 (median 80, 1.9x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Merck Sharp & Dohme LLC
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Merck Sharp & Dohme + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-16
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Merck Sharp & Dohme LLC and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Merck Sharp & Dohme LLC's enrollment: 71st percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 150 participants planned.
What is the ClinicalTrialStartPulse record for Merck Sharp & Dohme LLC?
Merck Sharp & Dohme LLC registered a Phase 3 study (NCT07821944) in Hyperlipidemia targeting 150 participants, posted 2026-09-16.
How does Merck Sharp & Dohme LLC compare to other ClinicalTrialStartPulse records?
Its enrollment of 150 sits in the upper half (71th percentile) of 8,879 records; the median is 80. It is 49 days old; check the official source for later updates before acting.
Merck Sharp & Dohme LLC vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC | NONUS | 150 | 71st | 2026-09-16 |
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Merck Sharp & Dohme LLC and peer phase 3 records
Get new ClinicalTrialStartPulse records like Merck Sharp & Dohme LLC by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.